Monitor clinical trials by sponsor or disease

1,851 trials changed in the last 7 days: 65 stopped, 855 with notable changes, 931 with minor changes only.

1. Stopped

   PF-06835375 in Primary Immune Thrombocytopenia

   Trial terminated

   Also in this update: Trial sites reduced: 31 → 24 locations; Primary completion date changed from estimate of Aug 2, 2028 to Sep 23, 2026

   Pfizer·Phase 2· NCT05070845· Registry history of NCT05070845 on ClinicalTrials.gov (opens the registry)

   Oct 16, 2026

2. Stopped

   Lp(a) Lowering Study of Pelacarsen (TQJ230) in Patients in the US…Lp(a) Lowering Study of Pelacarsen (TQJ230) in Patients in the US With Elevated Lp(a) and Recent ACS (STEMI/NSTEMI) - Lp(a)FRONTIERS PEARL

   Withdrawn before enrolling

   Also in this update: Primary and study completion pushed from Dec 7, 2028 to Jan 22, 2029

   Novartis Pharmaceuticals·Phase 3· NCT07625306· Registry history of NCT07625306 on ClinicalTrials.gov (opens the registry)

   Oct 14, 2026

3. Stopped

   LNP023 · Active Lupus Nephritis Class III-IV, +/- V

   Trial terminated

   Also in this update: Trial sites reduced: 103 → 74 locations; Study completion date changed from estimate of Sep 28, 2028 to Oct 1, 2026

   Novartis Pharmaceuticals·Phase 2· NCT05268289· Registry history of NCT05268289 on ClinicalTrials.gov (opens the registry)

   Oct 15, 2026

4. Stopped

   VAY RE-HIT · Ianalumab · Primary Immune Thrombocytopenia (ITP)…VAY RE-HIT · Ianalumab · Primary Immune Thrombocytopenia (ITP) and Warm-antibody Autoimmune Hemolytic Anemia (wAIHA) Who Have Previously Benefited From Ianalumab

   Trial status changed: Recruiting → Withdrawn

   Also in this update: Trial sites reduced: 25 → 0 locations

   Novartis Pharmaceuticals·Phase 2· NCT07039422· Registry history of NCT07039422 on ClinicalTrials.gov (opens the registry)

   Oct 15, 2026

5. Stopped

   SURVEYOR · MOON101 · Peanut Allergy

   Trial status changed: Active, Not Recruiting → Suspended

   Moonlight Therapeutics, Inc.·Phase 1· NCT07580898· Registry history of NCT07580898 on ClinicalTrials.gov (opens the registry)

   Oct 16, 2026

6. Stopped

   HEC169096 · Advanced Solid Tumors

   Trial terminated

   Also in this update: Final enrollment: 24 participants — 5% of the 456 planned; Primary completion date changed from estimate of Dec 30, 2026 to Sep 23, 2025

   Sunshine Lake Pharma Co., Ltd.·Phase 1/2· NCT05451602· Registry history of NCT05451602 on ClinicalTrials.gov (opens the registry)

   Oct 14, 2026

7. Stopped

   AG10 · Cardiomyopathy

   Trial terminated

   Also in this update: Primary endpoint(s) modified; Results posted: Oct 14, 2026

   Eidos Therapeutics, a BridgeBio company·Phase 2· NCT03536767· Registry history of NCT03536767 on ClinicalTrials.gov (opens the registry)

   Oct 14, 2026

8. Stopped

   Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent…Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Participants

   Trial terminated

   Also in this update: Study completion date changed from estimate of Jul 2028 to Jun 19, 2026; Final enrollment: 5 participants (planned 40)

   Iovance Biotherapeutics, Inc.·Phase 1· NCT06566092· Registry history of NCT06566092 on ClinicalTrials.gov (opens the registry)

   Oct 16, 2026

9. Stopped

   Weekly Oral Dose of Ecnoglutide (VRB-101) for Weight Maintenance…Weekly Oral Dose of Ecnoglutide (VRB-101) for Weight Maintenance · Obesity or Overweight With Weight-Related Comorbidities

   Trial terminated

   Also in this update: Final enrollment: 8 participants — 7% of the 120 planned; Primary completion date changed from estimate of Nov 30, 2026 to Sep 11, 2026

   Verdiva Bio Dev Limited·Phase 2· NCT07553299· Registry history of NCT07553299 on ClinicalTrials.gov (opens the registry)

   Oct 13, 2026

10. Stopped

    ENERGY · ENERGY Study: Evaluation of Safety and Tolerability of…ENERGY · ENERGY Study: Evaluation of Safety and Tolerability of INZ-701 · ENPP1 Deficiency or ABCC6 Deficiency

    Trial terminated

    Also in this update: Final enrollment: 9 participants (planned 16)

    Inozyme Pharma·Phase 1· NCT05734196· Registry history of NCT05734196 on ClinicalTrials.gov (opens the registry)

    Oct 15, 2026

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.